RU2002129569A - Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора - Google Patents
Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора Download PDFInfo
- Publication number
- RU2002129569A RU2002129569A RU2002129569/15A RU2002129569A RU2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569/15 A RU2002129569/15 A RU 2002129569/15A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A
- Authority
- RU
- Russia
- Prior art keywords
- hypertension
- renal failure
- pharmaceutically acceptable
- combination
- restenosis
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title claims 9
- 239000003112 inhibitor Substances 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 10
- 208000001647 Renal Insufficiency Diseases 0.000 claims 8
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 8
- 208000020832 chronic kidney disease Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000006370 kidney failure Diseases 0.000 claims 8
- 208000010125 myocardial infarction Diseases 0.000 claims 8
- 208000037803 restenosis Diseases 0.000 claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 6
- 208000029078 coronary artery disease Diseases 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 4
- 108010035532 Collagen Proteins 0.000 claims 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 238000002399 angioplasty Methods 0.000 claims 4
- 230000001028 anti-proliverative effect Effects 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 229920001436 collagen Polymers 0.000 claims 4
- 239000002934 diuretic Substances 0.000 claims 4
- 230000001882 diuretic effect Effects 0.000 claims 4
- 230000001258 dyslipidemic effect Effects 0.000 claims 4
- 230000008694 endothelial dysfunction Effects 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 208000003532 hypothyroidism Diseases 0.000 claims 4
- 230000002989 hypothyroidism Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000004351 coronary vessel Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000005478 Saprisartan Substances 0.000 claims 1
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229950006241 saprisartan Drugs 0.000 claims 1
- 229960000651 tasosartan Drugs 0.000 claims 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19674200P | 2000-04-12 | 2000-04-12 | |
| US60/196,742 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002129569A true RU2002129569A (ru) | 2004-03-27 |
Family
ID=22726655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002129569/15A RU2002129569A (ru) | 2000-04-12 | 2001-04-10 | Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1282410A2 (zh) |
| JP (1) | JP2003530343A (zh) |
| KR (1) | KR20020089437A (zh) |
| CN (1) | CN1422152A (zh) |
| AR (1) | AR032316A1 (zh) |
| AU (2) | AU7393801A (zh) |
| BR (1) | BR0110079A (zh) |
| CA (1) | CA2405895A1 (zh) |
| HU (1) | HUP0301335A3 (zh) |
| IL (1) | IL152081A0 (zh) |
| MX (1) | MXPA02010091A (zh) |
| NO (1) | NO20024920L (zh) |
| NZ (1) | NZ521855A (zh) |
| PE (1) | PE20020082A1 (zh) |
| PL (1) | PL358459A1 (zh) |
| RU (1) | RU2002129569A (zh) |
| SK (1) | SK14612002A3 (zh) |
| WO (1) | WO2001076574A2 (zh) |
| ZA (1) | ZA200208204B (zh) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162759A1 (en) * | 2000-07-27 | 2003-08-28 | Ricardo Rocha | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| ATE551056T1 (de) * | 2002-12-27 | 2012-04-15 | Takeda Pharmaceutical | Mittel zur hemmung der körpergewichtszunahme |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| ITTO20040760A1 (it) * | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare |
| EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| EA012392B1 (ru) * | 2004-12-24 | 2009-10-30 | Крка, Д.Д. Ново Место | Твердая фармацевтическая композиция, содержащая валсартан |
| US9271963B2 (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
| BRPI1011657A2 (pt) | 2009-05-28 | 2019-04-16 | Novartis Ag | derivados aminopropiônicos substituídos como inibidores de neprilisina |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| KR20190025737A (ko) | 2011-07-08 | 2019-03-11 | 노파르티스 아게 | 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| MA38330B1 (fr) | 2013-02-14 | 2016-09-30 | Novartis Ag | Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre) |
| TN2016000031A1 (en) | 2013-07-25 | 2017-07-05 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成ａｐｅｌｉｎ多肽之生物結合物 |
| PE20171328A1 (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de acidos grasos y apelina sintetica con mayor vida media |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CA3040803A1 (en) * | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| EP3787623A1 (en) | 2018-05-03 | 2021-03-10 | Damian Pharma AG | R-fadrozole for use in the treatment of aldostonerism |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| CA2632790A1 (en) * | 1996-07-22 | 1998-01-29 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
| FR2766821A1 (fr) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| SI1096932T1 (sl) * | 1998-07-10 | 2008-04-30 | Novartis Pharma Ag | Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov |
-
2001
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/es not_active Application Discontinuation
- 2001-04-10 AR ARP010101698A patent/AR032316A1/es not_active Application Discontinuation
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/hu unknown
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/ru not_active Application Discontinuation
- 2001-04-10 PL PL01358459A patent/PL358459A1/xx not_active Application Discontinuation
- 2001-04-10 CN CN01807917A patent/CN1422152A/zh active Pending
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/sk unknown
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/ja active Pending
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/ko not_active Ceased
- 2001-04-10 AU AU7393801A patent/AU7393801A/xx active Pending
- 2001-04-10 IL IL15208101A patent/IL152081A0/xx unknown
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/pt not_active IP Right Cessation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/es not_active Application Discontinuation
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Application Discontinuation
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
-
2002
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
- 2002-10-11 NO NO20024920A patent/NO20024920L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405895A1 (en) | 2001-10-18 |
| KR20020089437A (ko) | 2002-11-29 |
| PE20020082A1 (es) | 2002-02-21 |
| MXPA02010091A (es) | 2003-02-12 |
| WO2001076574A2 (en) | 2001-10-18 |
| CN1422152A (zh) | 2003-06-04 |
| NZ521855A (en) | 2004-10-29 |
| AU2001273938B2 (en) | 2005-03-03 |
| HUP0301335A3 (en) | 2006-02-28 |
| NO20024920D0 (no) | 2002-10-11 |
| HUP0301335A2 (hu) | 2003-08-28 |
| IL152081A0 (en) | 2003-05-29 |
| SK14612002A3 (sk) | 2003-05-02 |
| EP1282410A2 (en) | 2003-02-12 |
| BR0110079A (pt) | 2002-12-31 |
| AU7393801A (en) | 2001-10-23 |
| AR032316A1 (es) | 2003-11-05 |
| WO2001076574A3 (en) | 2002-04-25 |
| ZA200208204B (en) | 2003-10-14 |
| PL358459A1 (en) | 2004-08-09 |
| JP2003530343A (ja) | 2003-10-14 |
| NO20024920L (no) | 2002-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002129569A (ru) | Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора | |
| JP2005533023A5 (zh) | ||
| AU753486B2 (en) | Method of treatment and pharmaceutical composition | |
| US9592231B2 (en) | Therapy for complications of diabetes | |
| US6204281B1 (en) | Method of treatment and pharmaceutical composition | |
| RU2008135692A (ru) | Комбинация органический х-соединений | |
| TW200406204A (en) | Combination of organic compounds | |
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| JP2010507602A5 (zh) | ||
| US20070293552A1 (en) | Antihypertensive therapy method | |
| JP2018502883A5 (zh) | ||
| EP1487424B1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| WO2017006254A1 (en) | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist | |
| JP2019536803A5 (zh) | ||
| CN100558359C (zh) | 肾小球病治疗剂 | |
| IL276474B2 (en) | Modified bisphenyl butanoic ester derivatives as nep inhibitors | |
| KR101099189B1 (ko) | 당뇨병성 신장병증을 치료하기 위한 피리딜술폰아미도피리미딘 | |
| RU2830555C2 (ru) | Телмисартан для лечения гипертонии у собак | |
| JP2010031006A (ja) | 有機化合物の使用 | |
| HK1036758B (zh) | 伐尔沙坦和钙通道阻滞剂的抗过敏组合物 | |
| CA2677822A1 (en) | Antihypertensive drug combination | |
| HK1180956A (zh) | 治療糖尿病的並發症 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070313 |